Pre- and postmenopausal women or men with Stage II (Stage IIA limited to max.  patients) or Stage III early invasive breast cancer
Unresected operable breast cancer stage II-III with primary tumor > . cm
Patients must be diagnosed with metastatic cytologically or histologically confirmed adenocarcinoma of the breast with HER over-expression or with newly diagnosed locally advanced (including inflammatory) breast cancer (LABC) with stage II-III disease; patients with metastatic (stage IV) disease (MBC) must have measurable lesions
Clinical stage I-III breast cancer with any invasive residual disease in the breast or axillary nodes following neoadjuvant chemotherapy including HER- directed treatment
Newly diagnosed clinical stage II or III ER+/HER+ breast cancer with complete surgical excision of the breast cancer after neoadjuvant therapy as the treatment goal
a diagnosis of stage I, II, or III breast cancer;
Diagnosed with stage III colon or stage II/III rectal cancer that will receive neoadjuvant or adjuvant chemotherapy but have not yet started
Newly diagnosed clinical stage II or III breast cancer with complete surgical excision of the breast cancer after neoadjuvant chemotherapy as the treatment goal
Stage I-III (according to ENSAT classification ; see Appendix )
Patients must have Durie-Salmon stage II or III disease
Histologically confirmed infiltrating carcinoma of the breast (stage I-III)
ISS Stage III; or
ISS stage III; or
Subjects with HER- expressing stage I  III breast cancer with residual disease in the breast or axillary nodes post-neoadjuvant chemotherapy
Stage III A or B disease with minimum diagnostic evaluation within  weeks to include:
History of histologically-confirmed stage , I, II, or III breast carcinoma without evidence of disease at trial entry; participants with a resected local recurrence are eligible; site study physicians will review histology from documented pathology reports (which will be recorded in the Inclusion Criteria Case Report Form [CRF]); a separate consent will be obtained for release of medical records to document history of breast cancer diagnosis, staging, and treatment (which will be captured on the Medical History CRF); participants who have a documented history in their medical record of stage , I, II, or III breast carcinoma without evidence of disease at trial entry are eligible
Histologically confirmed, AJCC stage II or III breast cancer
Histologically confirmed invasive breast carcinoma, with all of the following characteristics: (i) Primary tumor greater than or equal to (>/=)  centimeters (cm) in largest diameter (cT-) by MRI; (ii) Stage I to operable Stage III breast cancer; (iii) Documented absence of distant metastases (M)
Part III:
Past history of treated (newly diagnosed or recurrent) breast, colorectal, prostate, gynecologic (only uterine and cervical) cancers (stage I, II, or III) or any stage lymphoma (Hodgkins or non-Hodgkins)
Planning to undergo adjuvant or neoadjuvant chemotherapy for stage I-III breast cancer
PHASE I: Diagnosis of stage I to III breast cancer
PHASE II: Diagnosis of stage I to III breast cancer
Survivors with a primary diagnosis of stage I-III breast, ovarian, uterine, or endometrial cancer
Women diagnosed with early stage, resectable breast cancer (Stage , I, II, or III) prior to age , and are within  years of diagnosis
Stage I-III
Diagnosis of stage II-III colon or rectal cancer planned for treatment with adjuvant chemotherapy scheduled as part of standard treatment
Newly diagnosed and surgically treated females with stage I-III breast cancer
- years post-completion of chemotherapy or/and radiation therapy for stage I-III breast cancer
Women newly diagnosed (stage I-III) breast cancer
Newly diagnosed with stage I-III breast cancer
Diagnosed with stage I, II, or III (a/b) breast cancer
Diagnosed with stage I-III lung cancer
Stage II-III breast cancer
Be diagnosed with breast cancer at stage , I, II, III or IV
Women newly diagnosed with stage I to III breast cancer who will be receiving adjuvant or neoadjuvant doxorubicin-based chemotherapy
Diagnosis of stage I to III breast cancer
Patients with stage I-III breast cancer
Participants must self-identify as having a medical history of histologically confirmed stage , I, II, III breast cancer, or I with no evidence of metastatic disease
Have a history of stage I, II, or III breast cancer
Mallampati I-III
Diagnosed with stage -III hormone-receptor positive breast cancer (BCa)
Diagnosed with early stage (I-III) breast cancer, without evidence of metastatic disease
Prior diagnosis of stage  to stage III breast cancer
Have a diagnosis of breast cancer (BC) (stage I-III)
Women with stage II or III breast cancer that will be scheduled to undergo a  to -week course of radiotherapy
Diagnosed with stage I-III colorectal cancer
Breast cancer stage I-III
Histologic or cytologic proven breast cancer or colon cancer (stage I, II or III)
Patients with early-stage breast cancer (stage I-III)
Have been diagnosed with stage -III breast cancer; bilateral or multiple primary breast cancers are permitted
Diagnosed with stage -III breast cancer within the past  years
A diagnosis of breast cancer, stage I, II, or III
Stage I-III gynecologic cancer (any site) or breast cancer
Women with stage -III breast cancer who will be undergoing daily adjuvant radiation for - weeks (patients only)
History of histologically or cytologically proven stage I-III breast cancer receiving intravenous chemotherapy on an every  days or every  days schedule
History of stage -III breast cancer
Has diagnosis of non-recurrent stage I-III breast cancer
Stage I-III
SCREENING PHASE: Histologically proven stage I-III carcinoma of the breast
INTERVENTION PHASE: Histologically proven stage I-III carcinoma of the breast
History of stage -III breast cancer or stage I-III ovarian cancer; all antitumor therapies, excluding hormonal therapy, have been completed at least  days prior to enrollment
Subjects with newly diagnosed stage I (T >  cm), II or III TNBC who have not undergone definitive breast surgery and have not received systemic chemotherapy will be eligible
History of histologically or cytologically proven breast cancer at stage I, II and III, without evidence of distant metastasis
History of histologically or cytologically proven breast cancer at stage I, II and III without evidence of distant metastasis
Stage I, II, and III prostate cancer
Diagnosis of stage  to III breast cancer
Newly diagnosed breast cancer (stage I, II, III)
Newly diagnosed with stage I-III breast cancer
Stage -III invasive carcinoma of the breast
Diagnosis of stage I, II, or III ovarian cancer
Patients with stage -III breast cancer, status-post surgery treated with standard chemotherapy/chemoprevention and/or radiation
History of stage I-III breast, gastrointestinal or gynecologic cancer
) Patients must have a diagnosis of breast cancer for which they must not have received or been scheduled for primary breast surgery at time of project intervention, and must be eligible for surgical resection (i.e. Stage I-III).
Stage I-III female breast cancer (including inflammatory and newly diagnosed, or locally recurrent but not metastatic breast cancer being treated with curative intent)
AJCC stage I - III non-inflammatory, HER-positive (according to ASCO-CAP guidelines ) breast cancer
Eligibility criteria will include: Postmenopausal women with of first incidence of early stage (stages  - III) hormone receptor positive breast cancer stabilized on anastrozole therapy for at least  months
The patient can undergo biopsy or surgery of a primary tumor site for suspected or proven invasive breast cancer of clinical stage I to III
Participants undergoing definitive surgery at diagnosis must have pathologic stage II or III disease
History of stage I-III breast cancer
Patients with primary stage I, II, III liver cancer or metastatic tumor in the liver from any cancer site
Women with stage I-III breast cancer who began their cancer treatment - years prior to this study and have received anthracycline based chemotherapy
A new diagnosis of invasive breast cancer > . cm in size, ER+ clinical stage I-III
No prior radiation therapy or systemic treatment is allowed for patients undergoing resection of stage I, II, or III colon cancer
Prior systemic therapy, radiotherapy, or investigational agent in participants undergoing surgery for stage I, II, or III colon cancer
AND diagnosed with Stage I-III incident breast or colorectal cancers;
Cancer Registry cases include stage I-III colon cancer (adenocarcinoma histology), stage I-III rectal cancer (adenocarcinoma histology), stage I-III non-small cell lung cancer (squamous or adenocarcinoma histology)
stage II-III, planned to be treated with radical surgery
